Vanishing White MatterNCT06594016
Expanded Access to Fosigotifator
A study testing Fosigotifator in people with Vanishing White Matter and Cree Leukoencephalopathy, run by AbbVie.
Trial summary
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Fosigotifator prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Vanishing White Matter, Cree Leukoencephalopathy
- What is being tested?
- Fosigotifator
- Type of treatment
- Pill or oral medicine
- How many people
- Not given
- Where
- No sites listed yet
- Study dates
- Start not givento not given
- Phase
- Expanded access
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
About this study
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Fosigotifator prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
- Conditions
- Vanishing White Matter, Cree Leukoencephalopathy
- Being tested
- Fosigotifator
- Keywords
- Expanded Access, Pre-approval Access, Compassionate Use, Special Access Program, Named Patient Basis, Special Access Scheme, Fosigotifator, FGT, ABBV-CLS-7262, 2025-10780, C25-693, Vanishing White Matter, Cree Leukoencephalopathy
- Medical subject headings
- Leukoencephalopathies
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
FosigotifatorDrug
Also called FGT, ABBV-CLS-7262
Oral
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Sep 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vanishing White MatterStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Expanded access
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06594016
- Sponsor's protocol ID
- 2025-10780
- Other IDs
- C25-693, 2025
- Status last verified
- Jan 2026
- First submitted
- 10 Sep 2024
- Last updated
- 14 Jan 2026
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Expanded Access to Fosigotifator
- ClinicalTrials.gov ID
- NCT06594016
- Acronym / sponsor ID
- 2025-10780
- Conditions
- Vanishing White Matter, Cree Leukoencephalopathy
- Keywords
- Expanded Access, Pre-approval Access, Compassionate Use, Special Access Program, Named Patient Basis, Special Access Scheme, Fosigotifator, FGT
- Study type
- Expanded access
- Recruitment status
- No Longer Available
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- First posted
- 19 Sep 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Fosigotifator prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Study design
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| FosigotifatorAlso: FGT, ABBV-CLS-7262Oral | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Jan 2026.
Related trials for Vanishing White Matter
RecruitingPhase 1/2
An Open-Label Exploratory Study of Fosigotifator in Participants With Vanishing White Matter Disease
Vanishing White Matter Disease
RecruitingObservational study
Longitudinal Study of Neurodegenerative Disorders
MLD, Krabbe Disease
Active, not recruiting
Single Patient Investigational Treatment for Cree Leukoencephalopathy
Cree Leukoencephalopathy
Active, not recruitingEarly Phase 1
Research Study for Single-Patient Treatment of Cree Leukoencephalopathy/Vanishing White Matter Disease
Cree Leukoencephalopathy, Vanishing White Matter
RecruitingObservational study
The Myelin Disorders Biorepository Project
Leukodystrophy, White Matter Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
ABBVIE INC. study director
AbbVie
Questions about this trial
What is this clinical trial studying?
A study testing Fosigotifator in people with Vanishing White Matter and Cree Leukoencephalopathy, run by AbbVie.
The full registered description is in the About this study section and the official record.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Jan 2026.